Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

Aileron Therapeutics

Status and phase

Completed

Phase 1

Conditions

Myelodysplastic Syndromes

Acute Myeloid Leukemia

Treatments

Drug: ALRN-6924

Drug: ALRN-6924 in combination with cytarabine

Study type

Interventional

Funder types

Industry

Identifiers

NCT02909972

ALRN-6924-1-02

Details and patient eligibility

About

Phase 1/1b, open label, multi-center dose escalation and dose expansion study designed to evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor effects of ALRN-6924 alone or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia or advanced myelodysplastic syndrome with wild-type (WT) TP53

Full description

Phase I, open label, multi-center dose escalation (DEP) and dose expansion (EXP) study designed to evaluate safety, tolerability, PK (pharmacokinetics), PD (pharmacodynamics) and anti-tumor effects of ALRN-6924 in patients with acute myeloid leukemia or advanced myelodysplastic syndrome with wild-type (WT) TP53. ALRN-6924 is a stabilized cell-permeating peptide designed to disrupt interaction between the p53 tumor suppression protein and its endogenous inhibitors murine double minute 2 (MDM2) and murine double minute X (MDMX)

Men and women 18 years of age and older with relapsed or refractory acute myeloid leukemia or advanced myelodysplastic syndrome and for which standard treatment(s) are not available or are no longer effective can be enrolled. Treatment of patients in the DEP and EXP phases will continue in the study until documentation of disease progression, unacceptable toxicity, or patient or physician decision to discontinue study participation is made.

Enrollment

55 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Relapsed or refractory acute myeloid leukemia or IPSS-R intermediate/high/very high-risk MDS patients
Confirmed or anticipated wild-type TP53
ECOG (Eastern Cooperative Oncology Group) performance status 0-2
Adequate hepatic and renal function
Acceptable coagulation function
Negative serum or urine pregnancy test within 7 days prior to the first dose of ALRN-6924 for women of child-bearing potential
Sufficient wash out from prior therapies and recovery from all significant toxicities

Exclusion criteria

Patients are eligible for available approved standard therapies
Prior treatment with MDM2 inhibitor, with protocol specified exceptions
Patients with history of allogeneic stem cell transplantation
Leukemic blast counts of >25,000/µl
Deletion of chromosome 17, or del(17p)
Patients with evidence of current central nervous system leukemic involvement
Known hypersensitivity to any study drug component
History of coagulopathy
Prior specified cardiovascular risk factors
Clinically significant gastrointestinal bleeding within 6 months
Clinically significant third-space fluid accumulation
Pregnant or lactating females
Evidence of any serious and/or unstable pre-existing medical condition that would interfere with patient safety ability to provide informed consent
Active uncontrolled infection, including HIV/AIDS or Hepatitis B or C
Second malignancy within one year, with protocol specified exceptions